662 Statistical learning from clinical and immunogenomic variables to predict response and survival with PD-L1 inhibition in advanced urothelial cancer

662 Statistical learning from clinical and immunogenomic variables to predict response and survival with PD-L1 inhibition in advanced urothelial cancer

Bibliographic Details
Main Authors:	Benjamin Vincent, Wolfgang Beck, Tracy Rose, Matthew Milowsky, William Kim, Jeff Klomp
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Immunogenomics: Molecular hide and seek
by: Miretti Marcos M, et al.
Published: (2006-01-01)

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
by: Anniina Färkkilä, et al.
Published: (2020-03-01)

Immunogenomics and human disease /
by: Falus, Andras
Published: (2006)

Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
by: Anniina Färkkilä, et al.
Published: (2020-05-01)

Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
by: Donghai Xiong, et al.
Published: (2018-11-01)

Tumor immunogenomic signatures improve a prognostic model of melanoma survival
by: Leah Morales, et al.
Published: (2021-02-01)

Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer
by: Yuanyuan Shen, et al.
Published: (2020-02-01)

Immunogenomic analysis of the tumour microenvironment
by: Chi, Y
Published: (2022)

Correction: Tumor immunogenomic signatures improve a prognostic model of melanoma survival
by: Leah Morales, et al.
Published: (2023-03-01)

Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma
by: Bao, Riyue, et al.
Published: (2023)

Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications
by: Kristin Weiss, et al.
Published: (2023-01-01)

Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer
by: Jeffrey S. Damrauer, et al.
Published: (2022-11-01)

662 Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
by: Rohit Jain, et al.
Published: (2023-11-01)

Immunogenomic Biomarkers and Validation in Lynch Syndrome
by: Ramadhani Chambuso, et al.
Published: (2023-02-01)

Editorial: Genes, diseases, immunity and immunogenomics
by: Hifzur R. Siddique
Published: (2023-06-01)

Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer
by: Blaine Brower, et al.
Published: (2024-04-01)

Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications
by: Jessica Roelands, et al.
Published: (2017-10-01)

An immunogenomic signature for molecular classification in hepatocellular carcinoma
by: Weiwei Zhuang, et al.
Published: (2021-09-01)

Classification of gastric cancers based on immunogenomic profiling
by: Zhixian Liu, et al.
Published: (2021-01-01)

Immunological classification of gliomas based on immunogenomic profiling
by: Qiushi Feng, et al.
Published: (2020-11-01)

Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition
by: Hanwen Wang, et al.
Published: (2023-06-01)

Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419
by: Eric D. Routh, et al.
Published: (2022-07-01)

EAS662 - STRUCTURAL RETROFITTING TECHNOLOGY. NOVEMBER 2005
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2005)

14.662 Labor Economics II, Spring 2005
by: Autor, David H., et al.
Published: (2005)

14.662 Labor Economics II, Spring 2007
by: Pischke, Jorn-Steffen, et al.
Published: (2007)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
by: Joon Seon Song, et al.
Published: (2019-10-01)

Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility
by: Shravan Leonard-Murali, et al.
Published: (2024-04-01)

Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients
by: Qun Wang, et al.
Published: (2021-02-01)

Hierarchical Clustering of Cutaneous Melanoma Based on Immunogenomic Profiling
by: Jie Yu, et al.
Published: (2020-11-01)

Immunogenomic phases of COVID-19 and appropriate clinical management
by: Ibrahim C Haznedaroglu
Published: (2020-11-01)

Construction of an Immunogenomic Risk Score for Prognostication in Colon Cancer
by: Han Zhang, et al.
Published: (2020-05-01)

Sex-specific differences in immunogenomic features of response to immune checkpoint blockade
by: Susan C. Scott, et al.
Published: (2022-08-01)

Immunogenomic profile at baseline predicts host susceptibility to clinical malaria
by: Gillian Mbambo, et al.
Published: (2023-07-01)

EAS662 – Structural Retrofitting Technology Duration : 2 hours
by: Awam, Pusat Pengajian Kejuruteraan
Published: (2022)

EAS662 – Structural Retrofitting Technology Duration : 2 hours
by: Awam, Pusat Pengajian Kejuruteraan
Published: (2021)

EAS 662/4 - TEKNOLOGI PEMULIHAN STRUKTUR JUN 2008.
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2008)

EAS 662-4 - STRUCTURAL RETROFITTING TECHNOLOGY NOV 2008.
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2008)

EAS 662/4 - STRUCTURAL RETROFITTING TECHNOLOGY NOV 09.
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2009)

EAS 662-4 - STRUCTURAL RETROFTING TECHNOLOGY JANUARY 2013
by: PPKW, Pusat Pengajian Kejuruteraan Awam
Published: (2013)

EAS 662/4 - STRUCTURAL RETROFOTTING TECHNOLOGY NOV 2010.
by: PPKAW, Pusat Pengajian Kejuruteraan Awam
Published: (2010)